Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of N-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma in Conjunction With Rituximab

NCT02384954 is registered in ClinicalTrials.gov with Altor BioScience as lead sponsor.

NCT NCT02384954
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02384954 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of N-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma in Conjunction With Rituximab
Lead sponsor
Altor BioScience
Phase
Phase 1/2
Overall status
Terminated
Start date
April 17, 2015
Completion date
December 13, 2020
Enrollment
43 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory indolent b cell non-hodgkin lymphoma